Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib

被引：31
|
作者：
Marks, Asher M. [1 ]
Bindra, Ranjit S. [2 ]
DiLuna, Michael L. [3 ]
Huttner, Anita [4 ]
Jairam, Vikram [2 ]
Kahle, Kristopher T. [3 ]
Kieran, Mark W. [5 ]
机构：
[1] Yale Univ, Sch Med, Dept Pediat Hematol Oncol, 333 Cedar St,LMP 2073, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Radiat Oncol, New Haven, CT USA
[3] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA
[4] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[5] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷 / 05期
关键词：
AYA; BRAF inhibitor; BRAF V600E; CNS tumor; ganglioglioma; MEK inhibitor; STEM GANGLIOGLIOMA; DABRAFENIB; MELANOMA;
D O I：
10.1002/pbc.26969
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials. Monotherapy with vemurafenib has been associated with significant side effects, including rashes, papillomas, and squamous cell carcinomas. Here we describe an adolescent female with anaplastic ganglioglioma and significant skin reaction to vemurafenib with subsequent tumor response and tolerance to the BRAF/MEK inhibitor combination of dabrafenib and trametinib without recurrence of previous reaction.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
    Bourque, Melissa S.
    Salek, Marta
    Sabin, Noah D.
    Canale, Meredith
    Upadhyaya, Santhosh A.
    [J]. PEDIATRIC BLOOD & CANCER, 2021, 68 (04)
  • [2] BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
    Del Bufalo, Francesca
    Ceglie, Giulia
    Cacchione, Antonella
    Alessi, Iside
    Colafati, Giovanna Stefania
    Carai, Andrea
    Diomedi-Camassei, Francesca
    De Billy, Emmanuel
    Agolini, Emanuele
    Mastronuzzi, Angela
    Locatelli, Franco
    [J]. FRONTIERS IN ONCOLOGY, 2018, 8
  • [3] Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
    Lang, Matthias
    Longerich, Thomas
    Anamaterou, Chrysanthi
    [J]. THYROID RESEARCH, 2023, 16 (01)
  • [4] Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
    Matthias Lang
    Thomas Longerich
    Chrysanthi Anamaterou
    [J]. Thyroid Research, 16
  • [5] RECURRENT GANGLIOGLIOMA WITH BRAF V600E MUTATION RESPONSE TO VEMURAFENIB: CASE REPORT
    Aguilera, Dolly
    Mazewski, Claire
    Janss, Anna
    Castellino, Robert Craig
    Schniederjan, Matthew
    Hayes, Laura
    Brahma, Barun
    MacDonald, Tobey
    [J]. NEURO-ONCOLOGY, 2014, 16 : 61 - 61
  • [6] Pediatric BRAF (V600E)-Mutated Pancreatic Acinar Cell Carcinoma With Complete and Durable Response to Dabrafenib and Trametinib
    Cramer, Stuart
    Marcus, Matthew A.
    Ramkissoon, Shakti
    Szabo, Sara
    Pressey, Joseph G.
    [J]. JCO PRECISION ONCOLOGY, 2020, 4 : 801 - 805
  • [7] Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma
    Yau, Wing Hing
    Ameratunga, Malaka
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (05) : 1172 - 1174
  • [8] Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma
    Cebollero, Ana
    Puertolas, Teresa
    Pajares, Isabel
    Calera, Lourdes
    Anton, Antonio
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (04) : 458 - 462
  • [9] Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
    Seo, Takuji
    Noguchi, Emi
    Yoshida, Masayuki
    Mori, Taisuke
    Tanioka, Maki
    Sudo, Kazuki
    Shimomura, Akihiko
    Yonemori, Kan
    Fujiwara, Yasuhiro
    Tamura, Kenji
    [J]. CASE REPORTS IN ONCOLOGICAL MEDICINE, 2020, 2020
  • [10] Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
    Fasano, Morena
    Della Corte, Carminia Maria
    Caterino, Marianna
    Pirozzi, Mario
    Rauso, Raffaele
    Troiani, Teresa
    Martini, Giulia
    Napolitano, Stefania
    Morgillo, Floriana
    Ciardiello, Fortunato
    [J]. FRONTIERS IN MEDICINE, 2022, 8
12345